D-limonene / NRF2 Cancer Research Results

DL, D-limonene: Click to Expand ⟱
Features:
Limonene, an oil extracted from the peels of citrus fruits. d-Limonene, one of the common terpenes in nature

D-limonene — D-limonene is the naturally dominant citrus-peel enantiomer of limonene, a lipophilic monocyclic monoterpene used as a flavoring/fragrance compound and investigated as an oral anticancer or chemopreventive bioactive. It is best classified as a small-molecule dietary monoterpene / terpene phytochemical rather than an approved oncology drug. Standard abbreviations include DL, d-LIM, and sometimes limonene when the D-enantiomer is implied. Its main natural source is citrus peel oil, especially orange peel oil. Its cancer relevance is supported mainly by preclinical studies plus small human pharmacokinetic and breast-tissue biomarker studies, with no established clinical oncology indication.

Primary mechanisms (ranked):

  1. Disruption of mevalonate-linked prenylation signaling, including Ras/Rho-associated growth and survival signaling.
  2. Mitochondrial apoptosis induction with MMP loss, Bax/Bcl-2 shift, caspase activation, and PARP cleavage.
  3. Cell-cycle suppression, especially reduced cyclin D1 signaling and proliferation arrest in breast-tissue translational studies.
  4. Autophagy-associated stress response that can contribute to apoptosis in some lung and other cancer models.
  5. ROS elevation and antioxidant depletion in cancer cells at active experimental concentrations, with context-dependent cytotoxic redox stress.
  6. Anti-inflammatory signaling modulation, including suppression of NF-κB-linked cytokine pathways.
  7. Anti-angiogenic and anti-metastatic effects, including VEGF-linked effects in selected models.
  8. Chemosensitization in selected models, including reported enhancement of docetaxel or tamoxifen cytotoxicity.

Bioavailability / PK relevance: D-limonene is orally bioavailable but highly lipophilic and extensively metabolized, with perillic acid and dihydroperillic acid among major human metabolites. Human oncology dosing has required gram-scale exposure; a phase I study reported an oral MTD of 8 g/m2/day with gastrointestinal dose-limiting toxicity. Peak plasma concentration (Cmax) for D-limonene ranged from 10.8+/-6.7 to 20.5+/-11.2 microM. Breast-tissue studies show distribution into human breast tissue, supporting local tissue exposure despite limited systemic biomarker effects. 2 g/day oral d-limonene for 2–6 weeks Breast tissue mean 41.3 µg/g tissue ≈ ~303 µM tissue-equivalent

In-vitro vs systemic exposure relevance: Many anticancer in-vitro studies use concentration ranges that may exceed typical dietary or supplement-level systemic exposure, so direct translation from cell culture is weak unless tissue accumulation or high-dose formulation exposure is demonstrated. Active clinical exposures are more relevant for lipophilic tissue compartments than for plasma-only comparisons. Mechanisms such as cyclin D1 modulation in human breast tissue are more translationally grounded than high-concentration ROS cytotoxicity assays.

Clinical evidence status: Small human / early phase. D-limonene has phase I pharmacokinetic data in advanced solid tumors and short presurgical breast cancer biomarker data, but no large RCT evidence and no regulatory approval as an anticancer therapy. Current use should be considered investigational or adjunct-research context only.

Fresh orange peel concerns: Eating fresh sweet orange peel can provide dietary D-limonene and polyphenols, but practical concerns include pesticide or wax residues and possible citrus-drug interaction caution in medication users. Risk can be minimized by using fresh organic or unwaxed sweet oranges, washing and scrubbing the peel, using mostly outer zest rather than thick pith, and storing grated peel refrigerated or frozen. Maximize D-limonene : Use fresh zest, frozen zest, or freeze-dried peel powder.

D-limonene Cancer Mechanism Matrix

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Mevalonate prenylation signaling Ras/Rho prenylation ↓; proliferation ↓ Likely lower impact at dietary exposure G Growth signaling suppression Mechanistically central for monoterpene anticancer biology; strongest relevance where tumors rely on prenylated small GTPase signaling.
2 Mitochondrial apoptosis MMP ↓; Bax ↑; Bcl-2 ↓; caspase-3 ↑; caspase-9 ↑; PARP cleavage ↑ Usually less cytotoxic at comparable non-transformed model exposure G Intrinsic apoptosis induction MMP↓, Bcl-2↓, and Casp3↑ tags; common endpoint across leukemia, colon, lung, and breast cancer models.
3 Cell-cycle and cyclin D1 signaling Cyclin D1 ↓; G1 arrest ↑; proliferation ↓ Limited direct normal-cell evidence G Proliferation arrest Human breast-tissue data make this one of the more translationally credible axes.
4 Autophagy linked apoptosis Autophagy ↑; apoptosis ↑ Context-dependent G Stress-amplified tumor cell death Autophagy appears pro-death in selected models but should be marked model-dependent because autophagy can also be adaptive.
5 Mitochondrial ROS increase ROS ↑; GSH ↓; oxidative stress ↑ Antioxidant protection ↑ in oxidative-injury models R/G Redox stress in cancer cells Useful but concentration-sensitive; cancer-cell ROS findings should not be generalized to all systemic exposures.
6 NRF2 and antioxidant response Mixed or insufficiently defined Antioxidant defense ↑ (context-dependent) G Context-dependent cytoprotection NRF2 is not the core anticancer mechanism for D-limonene; include only when specific studies show NRF2/HO-1 modulation in the model being indexed.
7 NF-κB inflammatory signaling NF-κB linked cytokine signaling ↓; inflammatory survival signaling ↓ Inflammatory injury ↓ R/G Anti-inflammatory modulation More strongly supported in inflammatory disease models than direct oncology trials, but relevant to tumor-promoting inflammation.
8 VEGF angiogenesis and metastasis VEGF signaling ↓; angiogenesis ↓; invasion/metastasis ↓ Potential wound-healing relevance uncertain G Anti-angiogenic and anti-invasive effect Supported mainly by preclinical cancer models and volatile-oil preparations enriched in D-limonene.
9 Glycolysis and HIF-1α Not a primary established axis Not established G Secondary or indirect metabolic effect
10 Chemosensitization Docetaxel effect ↑; tamoxifen effect ↑ (model-dependent) Normal-cell toxicity not consistently increased in available models G Adjunct cytotoxicity enhancement Preclinical adjunct signal only; timing, dose, formulation, and tumor context should be indexed carefully.
11 Clinical Translation Constraint Clinical antitumor efficacy unproven GI intolerance at high oral doses; skin irritation or sensitization possible with concentrated topical exposure G Exposure and evidence limitation Food-flavor GRAS status does not equal oncology-dose safety; clinical data remain small and non-definitive.

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr
NRF2, nuclear factor erythroid 2-related factor 2: Click to Expand ⟱
Source: TCGA
Type: Antiapoptotic
Nrf2 is responsible for regulating an extensive panel of antioxidant enzymes involved in the detoxification and elimination of oxidative stress. Thought of as "Master Regulator" of antioxidant response.
-One way to estimate Nrf2 induction is through the expression of NQO1.
NQO1, the most potent inducer:
SFN 0.2 μM,
quercetin (2.5 μM),
curcumin (2.7 μM),
Silymarin (3.6 μM),
tamoxifen (5.9 μM),
genistein (6.2 μM ),
beta-carotene (7.2μM),
lutein (17 μM),
resveratrol (21 μM),
indol-3-carbinol (50 μM),
chlorophyll (250 μM),
alpha-cryptoxanthin (1.8 mM),
and zeaxanthin (2.2 mM)

1. Raising Nrf2 enhances the cell's antioxidant defenses and ↓ROS. This strategy is used to decrease chemo-radio side effects.
2. Downregulating Nrf2 lowers antioxidant defenses and ↑ROS. In cancer cells this leads to DNA damage, and cell death.
3. However there are some cases where increasing Nrf2 paradoxically causes an increase in ROS (cancer cells). Such as cases of Mitochondial overload, signal crosstalk, reductive stress

-In some cases, Nrf2 is overexpressed in cancer cells, which can lead to the activation of genes involved in cell proliferation, angiogenesis, and metastasis. This can contribute to the development of resistance to chemotherapy and targeted therapies.
-Increased Nrf2 expression: Lung, Breast, Colorectal, Prostrate.
Decreased Nrf2 expression: Skine, Liver, Pancreatic.
-Nrf2 is a cytoprotective transcription factor which demonstrated both a negative effect as well as a positive effect on cancer
- "promotes Nrf2 translocation from the cytoplasm to the nucleus," means facilitates the movement of Nrf2 into the nucleus, thereby enhancing the cell's antioxidant and cytoprotective responses. -Major regulator of Nrf2 activity in cells is the cytosolic inhibitor Keap1.

Nrf2 Inhibitors and Activators
Nrf2 Inhibitors: Brusatol, Luteolin, Trigonelline, VitC, Retinoic acid, Chrysin
Nrf2 Activators: SFN, OPZ EGCG, Resveratrol, DATS, CUR, CDDO, Api
- potent Nrf2 inducers from plants include sulforaphane, curcumin, EGCG, resveratrol, caffeic acid phenethyl ester, wasabi, cafestol and kahweol (coffee), cinnamon, ginger, garlic, lycopene, rosemany

Nrf2 plays dual roles in that it can protect normal tissues against oxidative damage and can act as an oncogenic protein in tumor tissue.
– In healthy tissues, NRF2 activation helps protect cells from oxidative damage and maintains cellular homeostasis.
– In many cancers, constitutive activation of NRF2 (often through mutations in NRF2 itself or loss-of-function mutations in KEAP1) leads to an enhanced antioxidant capacity.
– This upregulation can promote tumor cell survival by enabling cancer cells to thrive under oxidative stress, resist chemotherapeutic agents, and sustain metabolic reprogramming.
– Elevated NRF2 levels have been implicated in promoting tumor growth, metastasis, and resistance to therapy in various malignancies.
– High or sustained NRF2 activity is frequently associated with aggressive tumor phenotypes, poorer prognosis, and decreased overall survival in several cancer types.
– While its activation is essential for protecting normal cells from oxidative stress, aberrant or sustained NRF2 activation in tumor cells can lead to enhanced survival, therapeutic resistance, and tumor progression.

NRF2 inhibitors: (to decrease antioxidant defenses and increase cell death from ROS).
-Brusatol: most cited natural inhibitors of Nrf2.
-Luteolin: luteolin can reduce Nrf2 activity in specific cancer models and may enhance cell sensitivity to chemotherapy. However, luteolin is also known as an antioxidant, and its influence on Nrf2 can sometimes be context dependent.
-Apigenin: certain studies to down‑regulate Nrf2 in cancer cells: Dose and context dependent .
-Oridonin:
-Wogonin: although its effects might be cell‑ and dose‑specific.
- Withaferin A

Scientific Papers found: Click to Expand⟱
6282- DL,    Limonene Exerts Anti-Inflammatory Effect on LPS-Induced Jejunal Injury in Mice by Inhibiting NF-κB/AP-1 Pathway
- in-vivo, IBD, NA
*RenoP↑, *creat↓, *Inflam↓, *TNF-α↓, *IL1β↓, *COX2↓, *ROS↓, *NRF2↑, *GastroP↑, *TLR4↓, *NF-kB↓, *AP-1↓, *Sepsis↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

NRF2↑, 1,   ROS↓, 1,  

Migration ⓘ

AP-1↓, 1,  

Barriers & Transport ⓘ

GastroP↑, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   IL1β↓, 1,   Inflam↓, 1,   NF-kB↓, 1,   TLR4↓, 1,   TNF-α↓, 1,  

Clinical Biomarkers ⓘ

creat↓, 1,  

Functional Outcomes ⓘ

RenoP↑, 1,  

Infection & Microbiome ⓘ

Sepsis↓, 1,  
Total Targets: 13

Scientific Paper Hit Count for: NRF2, nuclear factor erythroid 2-related factor 2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:68  Target#:226  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page